View more job listings or post a job
Bioduro-Sundia Associate Director/Director in Laboratory Animal and Exploratory Toxicology
Variant Bio (Senior) Scientist - DMPK
Alturas Analytics Scientist 1
Eli Lilly and Company R-39973 Scientific Director ADME - Novel Modalities (Open)
FibroGen Director DMPK
Applied BioMath Technical Marketing Specialist
Horizon Therapeutics Director, Bioanalytical Sciences
Exelixis Principal Scientist - DMPK
Post a job


[In-Person] Human Mass Balance and Metabolite Profiling Studies: Strategies, Technical Approaches, Regulatory Guidance, Applications and Case Studies

Speakers: Chandra Prakash, Agios; Zhixia Yan, FDA; Bernard Murray, Gilead; Ryan Takahashi, Denali Therapeutics; Shuai Wang, Genentech; Raman Sharma, Pfizer; Ronald Kong, PTC Therapeutics, Inc.
Organizers: Chandra Prakash (Agios)
Date: 2024-05-06
Time: 8:45-17:00 Pacific Time
Registration fee: Regular attendees: $295; Academic/Students/Postdocs: $45; Out-of-Pocket: $45; Major Sponsorship: $3000; Vendor Show: $695, Happy Hour Sponsorship: $975; Lunch Sponsorship: $1250; On-site Registration: $500
Location: Crowne Plaza, Foster City, CA (San Francisco Bay Area)
Major Sponsor: (2)Fortrea; Pharmaron
Vendor show vendors registered to date: (10)Celerion; Certara; Cyprotex; Discovery Life Sciences; Ellegaard BioResearch; Eurofins Selcia; Labcorp; MilliporeSigma [Sigma-Aldrich,Inc.]; Moravek, Inc.; Q Squared Solutions
Registration deadline:2024-05-05  (it will close sooner if the seating cap is reached)

About the Topic

Human absorption, distribution, metabolism, and excretion (ADME) study (also referred to as mass balance or radiolabel study) is a key study in the Clinical Pharmacology package of new drug application. The data gathered from this study provides a quantitative and comprehensive overall picture of the disposition of a drug, including excretion pattern and metabolite profiles in circulation and excreta and are highly informative for developing a cohesive strategy for clinical pharmacology studies, drug-drug interaction, organ impairment, monitoring of metabolite(s), and to obtain a waiver for the bioequivalence study.  Regulatory guidelines (Metabolites in Safety Testing, MIST) warrant that human specific or disproportionate metabolites whose exposure is greater than 10% of total drug related material should be considered for safety assessment in preclinical species. Recently, US Food and Drug Administration (FDA) issued a guidance describing the recommendations regarding clinical pharmacology considerations for conducting human radiolabeled mass balance studies of investigational drug.  

The workshop is designed to provide detailed guidance on objectives, study designs, and data analysis of metabolism studies of small molecules. Speakers of this workshop bring a wealth of knowledge from the pharmaceutical industry/FDA in drug metabolism sciences. This workshop will describe the highlights of this regulatory guidance and various strategies and technical approaches for conducting the human radiolabeled ADME studies with examples of approved drugs.

The discussion will be centered around the following topics:

  • Overview of the recent FDA guidance
  • Radiolabeled human ADME studies-why, what and when
  • Human ADME studies: Design, data analysis, and interpretation
  • Approaches for safety assessments of human metabolites
  • IV tracer studies approach with case studies


Time (PST)  Topic Presenter
8:45-8:55 am  PBSS Welcome and Introduction  Shichang Miao, PhD, PBSS 
8:55-9:20 am Objectives and Overview of Various Approaches Used for hADME Studies: Pros and Cons  Chandra Prakash, Senior Research Fellow, Agios Pharmaceuticals
9:20-9:50 am  Importance of Preclinical Radiolabeled ADME Studies Chandra Prakash, Senior Research Fellow, Agios Pharmaceuticals 
9:50 -10:30 am Nonclinical QWBA Studies and their Application in Human Dosimetry Calculations Bernard Murray, PhD, Executive Director, Drug Metabolism, Gilead Sciences
10:30-10:40 am Major Sponsor Presentation Fortrea
10:40-11:00 am Break and Vendor Show  -
11:00-11:50 am A Deep Dive: FDA Draft Guidance on Human Radiolabeled Mass Balance Studies Zhixia (Grace) Yan Danielsen, PhD, Deputy Division Director, US Food and Drug Administration 
11:50 am-12:50 pm Lunch Sponsor, TBD
12:50-1:40 pm Human Mass Balance and Metabolite Profiling: Design, Data Analysis, and Interpretation  Shuai Wang, PhD, Principal Scientist, DMPK, Genentech
1:40-2:30 pm hADME Studies at Steady State: Design and Case Studies Ronald Kong, PhD, Vice President, Clinical Pharmacology and DMPK, PTC Therapeutics. 
2:30-2:40 pm Major Sponsor Presentation Pharmaron
2:40-3:00 pm Break and Vendor Show 
3:00-3:50 pm Approaches for the Determination of Absolute Bioavailability: Study Design, Data Analysis, and Interpretation  Raman Sharma, Senior Scientist, Pfizer
3:50-4:30 pm Approaches for Coverage Assessment of Human Metabolites in Safety Species (MIST) Ryan Takahashi, PhD, Head of Small Molecule DMPK, Denali Therapeutics
4:30-5:00 pm Panel Discussion All speakers
5:00-6:00 pm Happy Hour Sponsor, Labcorp 



2024-04-26, [In-Person] Oncology Clinical Dose Optimization in Light of FDA Project Optimus
2024-05-13, [Free Online] Highlights of 2023 FDA Drug Approvals
2024-05-21, [In-Person] Nonclinical Safety Studies for IND and NDA Filing for Small Molecules: Nuts, Bolts and Best Practices
2024-05-30, [Free Online Workshop] Career Transition for Research Scientists: Career Overview, Project Management and Regulatory Affairs (jointly with BioPharmaPM and RAPS-SF)
2024-06-13, [In-Person] CMC Strategies and Activities for IND and NDA Filing for Small Molecules: Nuts, Bolts and Best Practices
2024-06-20, Alzheimer's Disease: untangling what we thought we knew and future Precision Medicine Diagnostics and Therapeutics
2024-07-24, [Free Online] The Science and Stories of Promising Biotech Startups: Symposium No.6
2024-09-10, [In-Person] Rethinking Translational PK/PD and Human Dose Projections for Novel Therapeutic Modalities: Covalent Inhibitors, PROTACs, Molecular Glues, ADCs, Ocular and Neuro delivery, Vaccines, Bispecifics, Cell and Gene Therapies
2024-09-20, [In-Person] Non-clinical safety assessments of biologics and novel modalities for IND/NDA Filing: Nuts, Bolts and Best Practices
2024-10-10, [In-Person] Regulatory Global Submission: Strategies and Best Practices for FDA, EMA and PMDA
┬ęPharmaceutical & BioScience Society, International; Last Modified: 4/23/2024; Admin Logon
Ads (in random order)
Submit a Text Ad
($250 for 2 months)

Alturas Analytics, Inc. Expert Regulated & Non-Regulated LC-MS, GC-MS bioanalytical & PK/TK analysis of small & large molecules in any matrix. Discovery through phase IV.
Hypha Discovery Synthesis, purification & NMR characterization of phase I and II drug metabolites & API impurities at mg-g scale with COAs.
Lena Biosciences Predictive toxicology. Intrinsic & idiosyncratic drug-induced liver injury. Mitochondrial toxicity in a drug metabolism-competent model.
Lena Biosciences Predictive toxicology. Mitochondrial toxicity in a drug metabolism-competent model with active transporters. Intrinsic & idiosyncratic DILI.
Submit a Text Ad